Paolo A. Ascierto

Ricercatore Oncologo presso Istituto Nazionale Tumori Fondazione Pascale di Napoli.
Medical oncologist from National Cancer Institute of Naples, Italy

[Yago Garitaonaindía @YGaritaonaindia]

🔥 Serum TKa in #BRAF metastatic #Melanoma - SECOMBIT trial in @CCR_AACR (subset, n=81)

Median split the cohort:

• 5-y OS 70.7% vs 36.9% (HR 3.08)
• 5-y total PFS 60.8% vs 35.0% (HR 2.47)
• Independent of LDH

➡️ TKa-high did better with the sandwich arm, TKa-low with upfront IO.

🎯 Good prognostic biomarker. 54% of TKa-high had normal LDH: aggressive biology you’d otherwise miss, in patients who need tumor control fast

👏@HildurHelg, @PAscierto & the rest of authors

https://t.co/9Jn3uOmOpR

[OncoDaily @oncodaily]

Honored to Receive the 2026 @sitcancer Lifetime Achievement Award - @PAscierto

https://t.co/Hm33rZ9L1w

[Paolo A. Ascierto @PAscierto]

@DrChoueiri @NatureMedicine @DanaFarber @DanaFarber_GU @harvardmed @GustaveRoussy @UnivParisSaclay @MarcMachaalani @ReneeSaliby @YaleIMed @derosa__lisa @CarolinaAlvesC5 Great paper!

[IRE ISG IFO @IREISGufficiale]

Oggi all'IRE la lecture del Prof. Ascierto ha aperto il convegno nazionale sul melanoma.
Nuovi standard terapeutici, vaccino a mRNA con dati a 5 anni solidi, e prospettive sulla tripla immunoterapia.
Leggi tutto → https://t.co/tylrZiLkdh

[Society for Immunotherapy of Cancer @sitcancer]

Now Published: Insights from @SITCancer experts on the surveillance and management of post-ICI delayed or chronic irAEs, including a call for an ICI RWD irAE registry. https://t.co/qz2Qe1lmPb
@PAscierto @kgunturuMD
#immunotherapy #survivorship

[Paolo A. Ascierto @PAscierto]

Why do IO combinations fail in adjuvant melanoma?
Because minimal residual disease lacks immune priming.
Adjuvant IO must activate immunity, not just maintain it.
With @IgnacioMelero | @jitcancer
https://t.co/NB9zzHbtbb

[Oncoinfo @Oncoinfo_it]

#ESMO25 | Melanoma ad alto rischio: follow up a 9 anni del CM-238 su nivolumab in adiuvante.
Il commento di Paolo A. Ascierto @PAscierto

Non perdere il contributo integrale sulla Day 3 di OncoInfo da Berlino 🔜

[Oncoinfo @Oncoinfo_it]

Melanoma resecato ad alto rischio: quali i dati a 9 anni del trial CheckMate 238 in adiuvante presentati a #ESMO25? E come si ridefinisce il ruolo di nivolumab in questo setting di pazienti? Lo abbiamo chiesto a @PAscierto https://t.co/GddfGoQztt

[Oncoinfo @Oncoinfo_it]

#ESMO25 | Melanoma ad alto rischio: follow up a 9 anni del CM-238 su nivolumab in adiuvante.
Il commento di @PAscierto 👇

Non perdere il contributo integrale sulla Day 3 di OncoInfo da Berlino 🔜

[OncLive.com @OncLive]

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma @PAscierto @UninaIT @istitutotumori @myESMO #ESMO25 #ESMO2025 #melsm #oncology
https://t.co/TKhOzGqHzQ

[CancerNetwork® @CancerNetwrk]

Best responses included a complete response rate of 11.7%, a partial response rate of 6.4%, and a stable disease rate of 37.2%. #ESMO25 #melsm | @myESMO @PAscierto

https://t.co/IwLEEf8I0N

[Toni Choueiri, MD @DrChoueiri]

Congrats 🎉 @PAscierto +team on the Nivolumab long-term data in Melanoma published in @NEJM during #ESMO25 !

@myESMO

[Science At BMS @ScienceAtBMS]

Tomorrow, Dr. @PAscierto will present the final, 9-year results from CheckMate 238, a double-blind, phase 3 study of adjuvant treatment trial in resected stage IIIB–C or stage IV #melanoma.

Join the session in Hall 7.1a at 14:45 CEST on Sat., Oct. 18 https://t.co/abWjumBY2E

[Roberto Burioni @RobertoBurioni]

FIno a poco fa un cancro metastatico nel quale due terapie erano fallite era una partita chiusa. Oggi, grazie alla medicina di precisione, è ancora tutta da giocare. Bellissimo lavoro tutto italiano appena uscito su @NatureMedicine dei miei amici @curijoey e @PAscierto

[Lucia Del Mastro @delmastro_lucia]

Al 10° Annual Meeting di Alleanza Contro il Cancro ho avuto l’onore di moderare una sessione con le letture magistrali del Prof. @curijoey e del Prof. @PAscierto.

Si è discusso di terapie agnostiche e oltre l’immunoterapia: le grandi aspettative per il futuro dell’oncologia.

[Paolo A. Ascierto @PAscierto]

Wishing Gordon Ramsay a speedy recovery after surgery for basal cell carcinoma.
His reminder to “use sunscreen” is more than advice-it’s prevention.
- The sun is not our enemy — UV radiation is
- Sunscreens don’t cause cancer: they protect against it.

[OncoDaily @oncodaily]

Every Sunburn Leaves a Mark - Raising Awareness on Skin Cancer Prevention - @PAscierto

https://t.co/1Ew9z5Otjk

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX

[AIM at Melanoma Foundation @AIMatMelanoma]

The FDA said no to a new treatment for advanced melanoma. We're collecting stories to help them understand what that means for real people.
Share your voice: https://t.co/wFEQ3vwiTt
#Melanoma #PatientVoices #FDA #AIMatMelanoma

[Paolo A. Ascierto @PAscierto]

Thanks to a request submitted @AIOM, the drug combination investigated in the NADINA trial, has been included among the treatments reimbursed by the Italian National Health Service (SSN) under Law 648/96, for use as neoadjuvant therapy in patients with melanoma.

[OncoDaily @oncodaily]

This is Where Ideas Capable of Improving and Transforming the World Take Place - Paolo Ascierto
@PAscierto

https://t.co/5TOjFW6lDy

#Cancer #CancerResearch #PremioFabula #Medicine #MedX #MedNews #MedEd #Health #Oncology #OncoDaily